Add to ORKGWe investigate the effect of availability of new drugs on survival from 17 types of cancer in 38 countries, controlling for all determinants of cancer survival that are invariant across cancer types within a given country, and that are invariant across countries for a given cancer type. We find that an increase in the number of available drugs is associated with an increase in both the one-year and the five-year survival rate. Also, the probability that a cancer drug has been launched in a country depends on the incidence of cancer cases eligible for treatment by that drug in that country
__Background__ Many new cancer medicines have been developed that can improve patients’ outcomes. Ho...
Background Survival for patients with cancer varies widely across Europe. This review is an ...
BACKGROUND: Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillan...
Cancer is a leading cause of death in developed countries, and cancer treatments are the top categor...
Background - Cancer survival varies widely between countries. The CONCORD study provides survival es...
BACKGROUND: Cancer survival varies widely between countries. The CONCORD study provides survival est...
Cancer survival is a key measure of the effectiveness of health-care systems. Persistent regional an...
Cancer policy differences might help to explain international variation in cancer survival, but empi...
SummaryBackgroundMortality rates from lung cancer are known to vary considerably between countries. ...
Cancer mortality has declined over the last three decades in most high-income countries reflecting i...
Cancer mortality has declined over the last three decades in most high-income countries reflecting i...
SummaryBackgroundCancer survival is a key measure of the effectiveness of health-care systems. Persi...
Background. Many new cancer medicines have been developed that can improve patients’ outcomes. Howev...
Background Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillanc...
SummaryBackgroundWorldwide data for cancer survival are scarce. We aimed to initiate worldwide surve...
__Background__ Many new cancer medicines have been developed that can improve patients’ outcomes. Ho...
Background Survival for patients with cancer varies widely across Europe. This review is an ...
BACKGROUND: Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillan...
Cancer is a leading cause of death in developed countries, and cancer treatments are the top categor...
Background - Cancer survival varies widely between countries. The CONCORD study provides survival es...
BACKGROUND: Cancer survival varies widely between countries. The CONCORD study provides survival est...
Cancer survival is a key measure of the effectiveness of health-care systems. Persistent regional an...
Cancer policy differences might help to explain international variation in cancer survival, but empi...
SummaryBackgroundMortality rates from lung cancer are known to vary considerably between countries. ...
Cancer mortality has declined over the last three decades in most high-income countries reflecting i...
Cancer mortality has declined over the last three decades in most high-income countries reflecting i...
SummaryBackgroundCancer survival is a key measure of the effectiveness of health-care systems. Persi...
Background. Many new cancer medicines have been developed that can improve patients’ outcomes. Howev...
Background Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillanc...
SummaryBackgroundWorldwide data for cancer survival are scarce. We aimed to initiate worldwide surve...
__Background__ Many new cancer medicines have been developed that can improve patients’ outcomes. Ho...
Background Survival for patients with cancer varies widely across Europe. This review is an ...
BACKGROUND: Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillan...